Safety concerns of sodium-glucose co-transporter-2 inhibitors in type 1 diabetes: A real-world study from the perspective of the Food and Drug Administration Adverse Event Reporting System

Diabetes Obes Metab. 2020 Nov;22(11):2204-2206. doi: 10.1111/dom.14138. Epub 2020 Aug 7.

Authors

Xiang Zhou¹, Yangzhong Zhou², Xuemei Li², Xinhua Xiao¹

Affiliations

¹ Department of Endocrinology, Key Laboratory of Endocrinology of National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
² Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

PMID: 32633000
DOI: 10.1111/dom.14138

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus, Type 1* / drug therapy
Glucose
Humans
Hypoglycemic Agents / adverse effects
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
Symporters*
United States / epidemiology
United States Food and Drug Administration

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
Glucose

Grants and funding